Temozolomide (for relapsed malignant glioma)

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC, Everfront Biotech Co., Ltd.

Conditions

AstrocytomaGliomaRecurrent Glioblastoma, IDH-Wildtype

Phase 2

Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

Not yet recruitingNCT07349693

Everfront Biotech Co., Ltd.Recurrent Glioblastoma, IDH-Wildtype

Start: 2027-04-01End: 2029-12-31Target: 175Updated: 2026-09-10

Unknown Phase

Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)

CompletedNCT00705198

Merck Sharp & Dohme LLCAstrocytoma, Glioma

Start: 2006-09-30End: 2016-07-31Updated: 2016-11-15

Related Papers

Resection and intracranial implant of (Z)- <i>n</i> -butylidenephthalide wafer followed by temozolomide as treatment for recurrent glioblastoma: A randomized phase IIb/III trial.

Journal of Clinical Oncology2026-05-28